Less than a year after Pharnext dropped its Alzheimer’s program over cost concerns, the French biotech has seen its lead program fail a phase 3 trial in a rare neurological disease.
Pharnext is walking away from its work developing a treatment for Alzheimer’s, saying additional development would be more money than the company is willing to spend.